MEDI 312-Discovery of YM155, a novel survivin suppressant for the treatment of cancer

被引：0
|
作者：
Kinoyama, Isao [1 ]
Matsuhisa, Akira [1 ]
Nakahara, Takahito [1 ]
Takeuchi, Masahiro [1 ]
Shirasuna, Kenna [1 ]
Minematsu, Tsuyoshi [1 ]
Asai, Norio [1 ]
Matsumoto, Shunichiro [1 ]
Kawaguchi, Kenichi [1 ]
Kazami, Junichi [1 ]
Toyoshima, Akira [1 ]
Kita, Aya [1 ]
Tominaga, Fumiko [1 ]
Okada, Minoru [1 ]
Ohta, Mitsuaki [1 ]
机构：
[1] Astellas Pharma Inc, Drug Discovery Res, Tsukuba, Ibaraki 3058585, Japan
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2007年 / 234卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
312-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines
    Michaelis, Martin
    Voges, Yvonne
    Rothweiler, Florian
    Weipert, Fabian
    Zia-Ahmad, Amara
    Cinatl, Jaroslav
    von Deimling, Andreas
    Westermann, Frank
    Roedel, Franz
    Wass, Mark N.
    Cinatl, Jindrich, Jr.
    CANCERS, 2020, 12 (03)
  • [32] Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS
    Minoda, Masaya
    Kawamoto, Teruya
    Ueha, Takeshi
    Kamata, Etsuko
    Morishita, Masayuki
    Harada, Risa
    Toda, Mitsunori
    Onishi, Yasuo
    Hara, Hitomi
    Kurosaka, Masahiro
    Akisue, Toshihiro
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (03) : 891 - 899
  • [33] Tumor regression induced by YM155, a novel, small molecule survivin suppressant, in experimental human lung tumor models.
    Nakahara, Takahito
    Takeuchi, Masahiro
    Kinoyama, Isao
    Kita, Aya
    Yamanaka, Kentaro
    Matsuhisa, Akira
    Sasamata, Masao
    CANCER RESEARCH, 2006, 66 (08)
  • [34] Tumor regression induced by YM155, a novel, survivin suppressant, in human diffuse large B-cell lymphoma models
    Kaneko, Naoki
    Kita, Aya
    Nakahara, Takahito
    Nakata, Mari
    Koutoku, Hiroshi
    Sasamata, Masao
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 260P - 260P
  • [35] Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
    Nakamura, Naoto
    Yamauchi, Tomohiro
    Hiramoto, Masashi
    Yuri, Masatoshi
    Naito, Masanori
    Takeuchi, Masahiro
    Yamanaka, Kentaro
    Kita, Aya
    Nakahara, Takahito
    Kinoyama, Isao
    Matsuhisa, Akira
    Kaneko, Naoki
    Koutoku, Hiroshi
    Sasamata, Masao
    Yokota, Hiroyuki
    Kawabata, Shigeki
    Furuichi, Kiyoshi
    MOLECULAR & CELLULAR PROTEOMICS, 2012, 11 (07)
  • [36] YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model
    Nakahara, Takahito
    Yamanaka, Kentaro
    Hatakeyama, Shinji
    Kita, Aya
    Takeuchi, Masahiro
    Kinoyama, Isao
    Matsuhisa, Akira
    Nakano, Kenji
    Shishido, Takao
    Koutoku, Hiroshi
    Sasamata, Masao
    ANTI-CANCER DRUGS, 2011, 22 (05) : 454 - 462
  • [37] Increase in resistance of cancer cells in confluent cultures to survivin inhibitor YM155
    Dolgikh, N. V.
    Chekanov, A. V.
    Akatov, V. S.
    FEBS JOURNAL, 2013, 280 : 310 - 310
  • [38] Induction of autophagy-dependent cell death by the survivin suppressant YM155 in salivary adenoid cystic carcinoma
    Yu-Fan Wang
    Wei Zhang
    Ke-Fei He
    Bing Liu
    Lu Zhang
    Wen-Feng Zhang
    Ashok B. Kulkarni
    Yi-Fang Zhao
    Zhi-Jun Sun
    Apoptosis, 2014, 19 : 748 - 758
  • [39] YM155 Reverses Statin Resistance in Renal Cancer by Reducing Expression of Survivin
    Nitta, Takashi
    Koike, Hidekazu
    Miyao, Takeshi
    Miyazawa, Yoshiyuki
    Kato, Haruo
    Furuya, Yosuke
    Sekine, Yoshitaka
    Suzuki, Kazuhiro
    ANTICANCER RESEARCH, 2017, 37 (01) : 75 - 80
  • [40] Pharmacokinetics, distribution and excretion of YM155 monobromide, a novel small-molecule survivin suppressant, in male and pregnant or lactating female rats
    Minematsu, Tsuyoshi
    Sonoda, Takuya
    Hashimoto, Tadashi
    Iwai, Megumi
    Oppeneer, Todd
    Felder, Laurie
    Shirai, Nobuaki
    Miyashita, Aiji
    Usui, Takashi
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2012, 33 (03) : 160 - 169
12345